The Potential of Serratiopetidase and Lumbrokinase for the Degradation of Prion Peptide 106-126 - an In Vitro and In Silico Perspective

Author(s): Sanjay Kisan Metkar, Suparna Ghosh, Agnishwar Girigoswami, Koyeli Girigoswami*.

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 18 , Issue 9 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: PrPC is a host-encoded prion protein, which gets post translationally modified into a transmissible, β-sheet rich disease associated protein called PrPSc, responsible for the Prion disease including mad cow disease in cattle and CJD in humans. The PrP 106-126 region in PrPSc peptide initiates the conformational change in that protein leading to fibrillation. Any agent that can destabilize or disintegrate such proteins can be served as a potential drug candidate for Prion diseases.

Methods: In the present study, an enzyme Lumbrokinase (LK) was isolated from earthworm and its activity was exploited towards PrP 106-126 amyloids in vitro along with another enzyme Serratiopeptidase (SP) taking Nattokinase (NK) as a standard.

Results: The results showed that PrP 106-126 amyloid formation was inhibited by both LK and SP, as evidenced from Thioflavin T fluorescence assay. Further, the size of fibrils as estimated by dynamic light scattering, was also found to be lower at different time intervals after incubation of the prion amyloids with LK and SP. Additionally, the molecular dynamics simulation revealed the thermodynamically favorable interaction of PrP 106-126 with LK as well as with SP with high affinity.

Conclusion: Finally, the toxicity of the disintegrated amyloids was assessed using PC12 cell lines which showed higher cell viability in case of LK and SP treated amyloids compared to only PrP 106- 126 amyloid treatment. Altogether, the study concluded that the serine proteases like LK and SP have the potential to disintegrate PrP 106-126 amyloids with improved cell viability. The in vivo studies are needed to be executed in future.

Keywords: Prion disease, Lumbrokinase, Serratiopeptidase, amyloid degradation, amyloidosis, fatal neurodegenerative disorders.

[1]
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216(4542): 136-44.
[http://dx.doi.org/10.1126/science.6801762] [PMID: 6801762]
[2]
Imran M, Mahmood S. An overview of human prion diseases. Virol J 2011; 8(1): 559.
[http://dx.doi.org/10.1186/1743-422X-8-559] [PMID: 22196171]
[3]
Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95(23): 13363-83.
[http://dx.doi.org/10.1073/pnas.95.23.13363] [PMID: 9811807]
[4]
Prusiner SB. Molecular biology and pathogenesis of prion diseases. Trends Biochem Sci 1996; 21(12): 482-7.
[http://dx.doi.org/10.1016/S0968-0004(96)10063-3] [PMID: 9009832]
[5]
Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003; 66: 21-33.
[http://dx.doi.org/10.1093/bmb/66.1.21] [PMID: 14522846]
[6]
Weissmann C. The state of the prion. Nat Rev Microbiol 2004; 2(11): 861-71.
[http://dx.doi.org/10.1038/nrmicro1025] [PMID: 15494743]
[7]
Veerhuis R, Boshuizen RS, Familian A. Amyloid associated proteins in Alzheimer’s and prion disease. Curr Drug Targets CNS Neurol Disord 2005; 4(3): 235-48.
[http://dx.doi.org/10.2174/1568007054038184] [PMID: 15975027]
[8]
Gupta S, Singhal NK, Ganesh S, Sandhir R. Extending arms of insulin resistance from diabetes to Alzheimer’s disease: Identification of potential therapeutic targets. CNS Neurol Disord Drug Targets 2019; 18(3): 172-84.
[http://dx.doi.org/10.2174/1871527317666181114163515] [PMID: 30430949]
[9]
Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993; 362(6420): 543-6.
[http://dx.doi.org/10.1038/362543a0] [PMID: 8464494]
[10]
Pérez M, Sadqi M, Muñoz V, Avila J, Avila J. Inhibition by Aplidine of the aggregation of the prion peptide PrP 106-126 into beta-sheet fibrils. Biochim Biophys Acta 2003; 1639(2): 133-9.
[http://dx.doi.org/10.1016/j.bbadis.2003.08.003] [PMID: 14559120]
[11]
Kanapathipillai M, Ku SH, Girigoswami K, Park CB. Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106-126. Biochem Biophys Res Commun 2008; 365(4): 808-13.
[http://dx.doi.org/10.1016/j.bbrc.2007.11.074] [PMID: 18039468]
[12]
Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 2005; 4(5): 587-96.
[http://dx.doi.org/10.2174/156800705774322076] [PMID: 16266291]
[13]
Chia KY, Ng KY, Koh RY, Chye SM. Single-chain Fv antibodies for targeting neurodegenerative diseases. CNS Neurol Disord Drug Targets 2018; 17(9): 671-9.
[http://dx.doi.org/10.2174/1871527317666180315161626] [PMID: 29546836]
[14]
Okoroma EA, Purchase D, Garelick H, et al. Enzymatic formulation capable of degrading scrapie prion under mild digestion conditions. PLoS One 2013; 8(7) e68099
[http://dx.doi.org/10.1371/journal.pone.0068099] [PMID: 23874511]
[15]
Hsu RL, Lee KT, Wang JH, Lee LY, Chen RP. Amyloid-degrading ability of nattokinase from Bacillus subtilis natto. J Agric Food Chem 2009; 57(2): 503-8.
[http://dx.doi.org/10.1021/jf803072r] [PMID: 19117402]
[16]
Metkar SK, Girigoswami A, Murugesan R, Girigoswami K. Lumbrokinase for degradation and reduction of amyloid fibrils associated with amyloidosis. J Appl Biomed 2017; 15(2): 96-104.
[http://dx.doi.org/10.1016/j.jab.2017.01.003]
[17]
Metkar SK, Girigoswami A, Murugesan R, Girigoswami K. In vitro and in vivo insulin amyloid degradation mediated by Serratiopeptidase. Mater Sci Eng C 2017; 70(Pt 1): 728-35.
[http://dx.doi.org/10.1016/j.msec.2016.09.049] [PMID: 27770948]
[18]
Henriques ST, Castanho MA. Is PrP(106-126) fragment involved in the membrane activity of the Prion protein? Curr Protein Pept Sci 2010; 11(5): 326-33.
[http://dx.doi.org/10.2174/138920310791330604] [PMID: 20423298]
[19]
Gavín R, Ureña J, Rangel A, et al. Fibrillar prion peptide PrP(106-126) treatment induces Dab1 phosphorylation and impairs APP processing and Abeta production in cortical neurons. Neurobiol Dis 2008; 30(2): 243-54.
[http://dx.doi.org/10.1016/j.nbd.2008.02.001] [PMID: 18374587]
[20]
Singh N, Gu Y, Bose S, Kalepu S, Mishra RS, Verghese S. Prion peptide 106-126 as a model for prion replication and neurotoxicity. Front Biosci 2002; 7: a60-71.
[http://dx.doi.org/10.2741/A740] [PMID: 11897566]
[21]
Gong H, He Z, Peng A, et al. Effects of several quinones on insulin aggregation. Sci Rep 2014; 4: 5648.
[http://dx.doi.org/10.1038/srep05648] [PMID: 25008537]
[22]
Girigoswami K, Ku SH, Ryu J, Park CB. A synthetic amyloid lawn system for high-throughput analysis of amyloid toxicity and drug screening. Biomaterials 2008; 29(18): 2813-9.
[http://dx.doi.org/10.1016/j.biomaterials.2008.03.022] [PMID: 18395792]
[23]
Dhanavade MJ, Jalkute CB, Barage SH, Sonawane KD. Homology modeling, molecular docking and MD simulation studies to investigate role of cysteine protease from Xanthomonas campestris in degradation of Aβ peptide. Comput Biol Med 2013; 43(12): 2063-70.
[http://dx.doi.org/10.1016/j.compbiomed.2013.09.021] [PMID: 24290922]
[24]
Eisenberg D, Lüthy R, Bowie JU. VERIFY3D: Assessment of protein models with three-dimensional profiles. Methods Enzymol 1997; 277: 396-404.
[http://dx.doi.org/10.1016/S0076-6879(97)77022-8] [PMID: 9379925]
[25]
Iman K, Mirza MU, Mazhar N, Vanmeert M, Irshad I, Kamal MA. In silico structure-based identification of novel acetylcholinesterase inhibitors against Alzheimer’s disease. CNS Neurol Disord Drug Targets 2018; 17(1): 54-68.
[http://dx.doi.org/10.2174/1871527317666180115162422] [PMID: 29336270]
[26]
Kamal MA, Shakil S, Nawaz MS, et al. Inhibition of butyrylcholinesterase with fluorobenzylcymserine, an experimental Alzheimer’s drug candidate: Validation of enzoinformatics results by classical and innovative enzyme kinetic analyses. CNS Neurol Disord Drug Targets 2017; 16(7): 820-7.
[http://dx.doi.org/10.2174/1871527316666170207160606] [PMID: 28176640]
[27]
Tang Y, Liang D, Jiang T, Zhang J, Gui L, Chang W. Crystal structure of earthworm fibrinolytic enzyme component A revealing the structural determinants of its dual fibrinolytic activity. J Mol Biol 2002; 321: 57-68.
[28]
Yamasaki H, Tsuji H, Saeki K. Anti-inflammatory action of a protease, TSP, produced by Serratia. Nihon Yakurigaku Zasshi Japan 1967; 63(4): 302-14.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 9
Year: 2019
Page: [723 - 731]
Pages: 9
DOI: 10.2174/1871527318666191021150002
Price: $65

Article Metrics

PDF: 25
HTML: 4